Advances in risk predictive performance of pre-symptomatic type 1 diabetes via the multiplex Antibody-Detection-by-Agglutination-PCR assay.

autoimmune diseases immunology islet autoantibodies pediatrics type 1 diabetes mellitus

Journal

Frontiers in endocrinology
ISSN: 1664-2392
Titre abrégé: Front Endocrinol (Lausanne)
Pays: Switzerland
ID NLM: 101555782

Informations de publication

Date de publication:
2024
Historique:
received: 18 11 2023
accepted: 22 01 2024
medline: 23 2 2024
pubmed: 23 2 2024
entrez: 23 2 2024
Statut: epublish

Résumé

Achieving early diagnosis of pre-symptomatic type 1 diabetes is critical to reduce potentially life-threatening diabetic ketoacidosis (DKA) at symptom onset, link patients to FDA approved therapeutics that can delay disease progression and support novel interventional drugs development. The presence of two or more islet autoantibodies in pre-symptomatic type 1 diabetes patients indicates high-risk of progression to clinical manifestation. Herein, we characterized the capability of multiplex ADAP assay to predict type 1 diabetes progression. We obtained retrospective coded sera from a cohort of 48 progressors and 44 non-progressors from the NIDDK DPT-1 study. The multiplex ADAP assay and radiobinding assays had positive predictive value (PPV)/negative predictive value (NPV) of 68%/92% and 67%/66% respectively. The improved NPV stemmed from 12 progressors tested positive for multiple islet autoantibodies by multiplex ADAP assay but not by RBA. Furthermore, 6 out of these 12 patients tested positive for multiple islet autoantibodies by RBA in subsequent sampling events with a median delay of 2.8 years compared to multiplex ADAP assay. In summary, multiplex ADAP assay could be an ideal tool for type 1 diabetes risk testing due to its sample-sparing nature (4µL), non-radioactiveness, compatibility with widely available real-time qPCR instruments and favorable risk prediction capability.

Identifiants

pubmed: 38390205
doi: 10.3389/fendo.2024.1340436
pmc: PMC10882067
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1340436

Informations de copyright

Copyright © 2024 Tandel, Hinton, de Jesus Cortez, Seftel, Robinson and Tsai.

Déclaration de conflit d'intérêts

DT, BH, FJC, PR, DS, and C-tT were employed by Enable Biosciences. FJC, DT, PR, DS, and C-tT are shareholders of Enable Biosciences. PR and C-tT are inventors of the ADAP patent licensed from University of California, Berkeley to Enable Biosciences. The ADAP assay used in this study is a product in development. This does not alter our adherence to journal policies on sharing data and materials.

Auteurs

Devangkumar Tandel (D)

Research & Product Development, Enable Biosciences, South San Francisco, CA, United States.

Brigette Hinton (B)

Research & Product Development, Enable Biosciences, South San Francisco, CA, United States.

Felipe de Jesus Cortez (F)

Research & Product Development, Enable Biosciences, South San Francisco, CA, United States.

David Seftel (D)

Research & Product Development, Enable Biosciences, South San Francisco, CA, United States.

Peter Robinson (P)

Research & Product Development, Enable Biosciences, South San Francisco, CA, United States.

Cheng-Ting Tsai (CT)

Research & Product Development, Enable Biosciences, South San Francisco, CA, United States.

Classifications MeSH